Over the past two decades, the importance of EGFR expression and mutations in lung cancer has been validated, and genomic medicine has led to improved treatments for patients with EGFR-mutated lung cancer [2,3,4,5,25,26]. This evidence concerns the gene EGFR and lung carcinoma.